Law360, New York (March 29, 2017, 6:23 PM EDT) -- Gene therapy research company GenVec Inc. was hit by a putative class action Tuesday in Delaware federal court by shareholders who say the company’s imminent acquisition by Intrexon Corp. gives them a raw deal and that the merger registration statement is inaccurate.GenVec shareholder Paul Parshall says the merger with Intrexon, announced in January, was rushed through with inadequate analysis, gives shareholders too little relative to GenVec’s actual worth, and involves an incorrect SEC registration statement. Intrexon is also listed as a defendant, as are a number of GenVec insiders.Intrexon, which deals with the engineering and industrialization of biology, announced... In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition. TRY LAW360 FREE FOR SEVEN DAYS
Gene therapy research firm catalyst has been served with a class action lawsuit in Delaware by attorneys who defended the company ’s acquisition by Intrexon , citing a lack of advantages and an inaccurate SEC registration statement .